Compare Adaptive Biotechnologies Corp (ADPT) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Prospect Capital Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Prospect Capital Corporation trades at $2.21 (market cap $1.10B). The key difference: Adaptive Biotechnologies Corp is far larger — about 3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PSEC | |
|---|---|---|
Market Cap | $3.33B | $1.10B |
Sector | Health | Financials |
52-Week High | $22.37 | $3.47 |
52-Week Low | $10.24 | $2.15 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 22.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Prospect Capital Corporation (PSEC) trades at $2.20, down 1.79% recently, with a bearish technical outlook. The stock shows mixed fundamentals with a low P/B ratio of 0.37 but concerning negative revenue and net income margins. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.16 exceeding the $0.1109 forecast. The company maintains regular dividend payments, recently completing a $328 million portfolio sale that generated a 4.8x return on investment.
PSEC presents a high-risk opportunity with its deep discount to NAV and 18%+ yield attracting income investors, but fundamental deterioration and analyst skepticism pose significant challenges. The bearish technical signals and negative cash flow trends suggest caution, while the company's shift toward first-lien lending may improve portfolio quality over time. Investment suitability depends on risk tolerance for BDC volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
